High rates of ofloxacin resistance in Mycobacterium tuberculosis among both new and previously treated patients in Tamil Nadu, South India.
Periodic drug resistance surveillance provides useful information on trends of drug resistance and effectiveness of tuberculosis (TB) control measures. The present study determines the prevalence of drug resistance among new sputum smear positive (NSP) and previously treated (PT) pulmonary TB patients, diagnosed at public sector designated microscopy centers (DMCs) in the state of Tamil Nadu, India. In this single-stage cluster-sampling prevalence survey, 70 of 700 DMCs were randomly selected using a probability-proportional to size method. A cluster size of 24 for NSP and a varying size of 0 to 99 for PT cases were fixed for each selected DMC. Culture and drug susceptibility testing was done on Lowenstein-Jensen medium using the economic variant of proportion sensitivity test for isoniazid (INH), rifampicin (RMP), ofloxacin (OFX) and kanamycin (KAN). Human Immunodeficiency Virus (HIV) status was collected from patient records. From June 2011 to August 2012, 1524 NSP and 901 PT patients were enrolled. Any RMP resistance and any INH resistance were observed in 2.6% and 15.1%, and in 10.4% and 30% respectively in NSP and PT cases. Among PT patients, multi drug resistant TB (MDR-TB) was highest in the treatment failure (35%) group, followed by relapse (13%) and treatment after default (10%) groups. Extensively drug resistant TB (XDRTB) was seen in 4.3% of MDR-TB cases. Any OFX resistance was seen in 10.4% of NSP, 13.9% of PT and 29% of PT MDR-TB patients. The HIV status of the patient had no impact on drug resistance levels. RMP resistance was present in 2.6% of new and 15.1% of previously treated patients in Tamil Nadu. Rates of OFX resistance were high among NSP and PT patients, especially among those with MDR-TB, a matter of concern for development of new treatment regimens for TB.
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
N
N
Selvakumar
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
Vanaja
V
Kumar
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
S
S
Balaji
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
S
S
Prabuseenivasan
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
R
R
Radhakrishnan
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
Gomathi
G
Sekar
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
V
V
Chandrasekaran
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
T
T
Kannan
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
Aleyamma
A
Thomas
State TB Cell, Government of Tamil Nadu, Chennai, India.
S
S
Arunagiri
WHO India, New Delhi, India.
Puneet
P
Dewan
National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India.
Soumya
S
Swaminathan
D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy / Q000453:epidemiology*
D000995:Antitubercular Agents; D015242:Ofloxacin